- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 16, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-09-05
DOI
10.1186/s13045-023-01499-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- (2023) Esther Schoutrop et al. Journal for ImmunoTherapy of Cancer
- LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
- (2023) Guoming Hu et al. Frontiers in Oncology
- Increasing cure rates of solid tumors by immune checkpoint inhibitors
- (2023) Weijie Ma et al. Experimental Hematology & Oncology
- STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
- (2023) Amer M Zeidan et al. Future Oncology
- Exploiting RIG-I-like receptor pathway for cancer immunotherapy
- (2023) Yangfu Jiang et al. Journal of Hematology & Oncology
- Novel strategies for cancer immunotherapy: counter-immunoediting therapy
- (2023) Shaochuan Liu et al. Journal of Hematology & Oncology
- Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
- (2023) Fan Yang et al. Frontiers in Immunology
- T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review
- (2023) Gerardo Cazzato et al. Cancers
- Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
- (2023) Yidan Qiao et al. Cancer Communications
- Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
- (2023) Mengke Niu et al. Journal of Hematology & Oncology
- TIGIT is a key inhibitory checkpoint receptor in lymphoma
- (2023) James Godfrey et al. Journal for ImmunoTherapy of Cancer
- Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
- (2022) Muthulekha Swamydas et al. Journal of Hematology & Oncology
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32
- (2022) Kang Wu et al. Frontiers in Pharmacology
- An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
- (2022) Xin Chen et al. Frontiers in Immunology
- The role of phosphatidylserine on the membrane in immunity and blood coagulation
- (2022) Jiao Wang et al. Biomarker Research
- Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer
- (2022) Marion Thibaudin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin's lymphoma
- (2022) Zachary Jackson et al. Cancer Discovery
- Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
- (2022) Franziska Blaeschke et al. Frontiers in Immunology
- Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR ‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
- (2022) Cunte Chen et al. Clinical and Translational Medicine
- Heterogeneity of the tumor immune microenvironment and its clinical relevance
- (2022) Qingzhu Jia et al. Experimental Hematology & Oncology
- Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
- (2022) Junfen Xu et al. CLINICAL CANCER RESEARCH
- Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).
- (2022) Gerald Steven Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
- (2022) Liangliang Xu et al. Journal of Hematology & Oncology
- Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses
- (2022) Markus Zettl et al. OncoImmunology
- 745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody
- (2022) K.S. Rohrberg et al. ANNALS OF ONCOLOGY
- 486P AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein, elicits potent anti-tumor efficacy in pre-clinical studies
- (2022) J. Min et al. ANNALS OF ONCOLOGY
- Negative Regulation of RIG-I by Tim-3 Promotes H1N1 Infection
- (2022) Qingzhu Shi et al. IMMUNOLOGICAL INVESTIGATIONS
- LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
- (2022) Natalia Sauer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
- (2022) Yuchen Wang et al. Journal of Hematology & Oncology
- The journey of CAR-T therapy in hematological malignancies
- (2022) Junru Lu et al. Molecular Cancer
- TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
- (2022) Vivian Changying Jiang et al. Molecular Cancer
- Immunotherapeutic progress and application of bispecific antibody in cancer
- (2022) Jingyue Kang et al. Frontiers in Immunology
- Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
- (2022) Marina Natoli et al. Journal for ImmunoTherapy of Cancer
- Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
- (2022) Diana Cortes-Selva et al. BLOOD
- A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
- (2022) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
- (2021) Matthew D. Hellmann et al. CLINICAL CANCER RESEARCH
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
- (2021) James J. Harding et al. CLINICAL CANCER RESEARCH
- LAG-3 expression in the inflammatory microenvironment of glioma
- (2021) Maximilian J. Mair et al. JOURNAL OF NEURO-ONCOLOGY
- Implication of TIGIT+ human memory B cells in immune regulation
- (2021) Md Mahmudul Hasan et al. Nature Communications
- Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
- (2021) Giuseppe Curigliano et al. CLINICAL CANCER RESEARCH
- Correction: Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2021) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Next generation of immune checkpoint inhibitors and beyond
- (2021) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment
- (2021) Sarah Jenkins et al. Current Oncology Reports
- Bispecific Antibodies: From Research to Clinical Application
- (2021) Jiabing Ma et al. Frontiers in Immunology
- One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
- (2021) Zhiding Wang et al. Frontiers in Immunology
- LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
- (2021) Lena Seifert et al. Cancers
- LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
- (2021) Christian Sordo-Bahamonde et al. Cancers
- LAG3 and its emerging role in cancer immunotherapy
- (2021) Miao Wang et al. Clinical and Translational Medicine
- Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors
- (2021) Antoine Hollebecque et al. CLINICAL CANCER RESEARCH
- AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
- (2021) Lingying Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
- (2021) Wenjing Qian et al. Journal of Hematology & Oncology
- Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
- (2021) Wen-Hsin Sandy Lee et al. MOLECULAR CANCER THERAPEUTICS
- Single‐Cell RNA‐Seq of T Cells in B‐ALL Patients Reveals an Exhausted Subset with Remarkable Heterogeneity
- (2021) Xiaofang Wang et al. Advanced Science
- TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
- (2021) Zhouhong Ge et al. Frontiers in Immunology
- PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow
- (2021) Ling Xu et al. Frontiers in Oncology
- The landscape of bispecific T cell engager in cancer treatment
- (2021) Shujie Zhou et al. Biomarker Research
- LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
- (2021) Gaëlle Rhyner Agocs et al. Journal of Personalized Medicine
- The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
- (2021) Andrea Botticelli et al. Journal of Personalized Medicine
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
- (2021) J. Niu et al. ANNALS OF ONCOLOGY
- Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents
- (2021) Andrew M. Brunner et al. BLOOD
- PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
- (2021) Young-Ho Lee et al. MOLECULAR THERAPY
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial
- (2021) Alan J. Korman et al. NATURE REVIEWS DRUG DISCOVERY
- Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
- (2021) Songbo Zhao et al. Journal for ImmunoTherapy of Cancer
- Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
- (2021) Peipei Wang et al. Journal for ImmunoTherapy of Cancer
- Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
- (2021) Franziska Brauneck et al. Frontiers in Medicine
- Recent advances and challenges of bispecific antibodies in solid tumors
- (2021) Yuze Wu et al. Experimental Hematology & Oncology
- Light-induced radiosynthesis of 89ZrDFO-azepin-onartuzumab for imaging the hepatocyte growth factor receptor
- (2020) Simon Klingler et al. JOURNAL OF NUCLEAR MEDICINE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- (2020) Hirofumi Ohmura et al. BRITISH JOURNAL OF CANCER
- FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
- (2020) Matthew Kraman et al. CLINICAL CANCER RESEARCH
- A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
- (2020) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- TIGIT enhances CD4 + regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model
- (2020) Fengzhen Chen et al. Cancer Medicine
- The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia
- (2020) Sara M. Radwan et al. HLA
- Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
- (2020) Adi Reches et al. Journal for ImmunoTherapy of Cancer
- A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
- (2020) Fang Yang et al. JOURNAL OF IMMUNOLOGY
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
- (2019) Sneha Berry et al. Journal for ImmunoTherapy of Cancer
- AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer
- (2019) Luc Dirix et al. Future Oncology
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1
- (2019) Irma Herrera-Camacho et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
- (2019) Yaru Tian et al. Journal of Hematology & Oncology
- Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
- (2019) Paola Dama et al. Journal for ImmunoTherapy of Cancer
- Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice
- (2019) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- 1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
- (2019) A Spreafico et al. ANNALS OF ONCOLOGY
- Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas
- (2019) Carlos A Murga-Zamalloa et al. JOURNAL OF CLINICAL PATHOLOGY
- TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
- (2019) Jiefei Han et al. Cancer Immunology Research
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells
- (2018) Dongliang Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT
- (2018) Long Liu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
- (2018) Marina Wierz et al. BLOOD
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- (2018) Xiaolei Li et al. Cellular & Molecular Immunology
- T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
- (2018) Long Liu et al. CLINICAL IMMUNOLOGY
- Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
- (2018) Bhagyashree Bhagwat et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
- (2018) Michael Hedvat et al. CANCER RESEARCH
- Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies
- (2018) David Savitsky et al. CANCER RESEARCH
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction and transcriptional regulation of the co-inhibitory gene module in T cells
- (2018) Norio Chihara et al. NATURE
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
- (2018) Sergey N. Zolov et al. CYTOTHERAPY
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
- (2018) Xiu-Man Zhou et al. Frontiers in Immunology
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Tim-3 as a therapeutic target in prostate cancer
- (2017) Yongrui Piao et al. TUMOR BIOLOGY
- High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
- (2017) Liangjing Xu et al. Oncotarget
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression
- (2016) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
- (2016) Zhu Li et al. MEDICINE
- LAG3 facilitates cell-to-cell spread of α-synuclein pathology
- (2016) Heather Wood Nature Reviews Neurology
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Dan R. Littman CELL
- A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
- (2015) Yoshikane Kikushige et al. Cell Stem Cell
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
- (2015) Christopher A. Fuhrman et al. JOURNAL OF IMMUNOLOGY
- Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell
- (2015) WENWU WANG et al. ONCOLOGY REPORTS
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
- (2015) Chiao-Wen Kang et al. Scientific Reports
- Tim-3 and Tim-4 as the potential targets for antitumor therapy
- (2015) Lin Cheng et al. Human Vaccines & Immunotherapeutics
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
- (2014) Nicole Joller et al. IMMUNITY
- Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II
- (2014) Bitao Liang et al. JOURNAL OF IMMUNOLOGY
- Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
- (2014) Robert L. Ferris et al. JOURNAL OF IMMUNOLOGY
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
- (2014) L. E. Macdonald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
- (2014) A. J. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer
- (2013) Yong-Rui Piao et al. Asian Pacific Journal of Cancer Prevention
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers
- (2013) YONGJUN SHANG et al. Oncology Letters
- Ectopic Expression of TIM-3 in Lung Cancers
- (2012) Xuewei Zhuang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
- (2012) Manu Rangachari et al. NATURE MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now